BioNexus Gene Lab Corp.

BGLC · NASDAQ
Analyze with AI
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Operating Activities
Net Income-$1,598-$2,629-$356$752
Dep. & Amort.$153$108$105$108
Deferred Tax$0$0$0$0
Stock-Based Comp.$0$0$0$0
Change in WC$115$118$833-$862
Other Non-Cash-$904$642-$31$12
Operating Cash Flow-$2,234-$1,761$552$9
Investing Activities
PP&E Inv.-$227-$149-$54-$3
Net Acquisitions$0$0$0$0
Inv. Purchases-$572-$321-$512-$516
Inv. Sales/Matur.$1,069$26$0$6
Other Inv. Act.$148-$1,412$115$22
Investing Cash Flow$418-$1,856-$450-$491
Financing Activities
Debt Repay.$0$0-$34-$26
Stock Issued$0$5,750$150$0
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$145$525-$8-$2
Financing Cash Flow$145$6,275$108-$28
Forex Effect$40$1,152-$215-$154
Net Chg. in Cash-$1,631$3,810-$5-$664
Supplemental Information
Beg. Cash$4,518$2,119$2,124$2,788
End Cash$2,887$5,929$2,119$2,124
Free Cash Flow-$2,461-$1,910$498$6
BioNexus Gene Lab Corp. (BGLC) Financial Statements & Key Stats | AlphaPilot